Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets


Out-
      side
 



 
 'Gadoterate Meglumine' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Gadoterate Meglumine' found in 1 term [] and 3 definitions []
1 - 4 (of 4)     
Result Pages : [1]
Searchterm 'Gadoterate Meglumine' was also found in the following service: 
spacer
News  (2)  
 
Gadoterate MeglumineInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Gd-DOTA, generic name: Gadoterate meglumine
Dotarem / [ Artirem® ] A paramagnetic MRI contrast agent for intravenous use. This agent is used as a routine clinical tool to reveal anatomical details in vivo and to detect lesions for diagnosis.
See also Contrast Agents.

spacer
 
• Share the entry 'Gadoterate Meglumine':  Facebook  Twitter  LinkedIn  
 
• Related Searches:
    • Guerbet S.A.
    • Contrast Agents
    • Paramagnetic Chemical Exchange Saturation Transfer
    • Paramagnetic Substance
    • Paramagnetic Contrast Agents
MRI Resources 
Sequences - MR Myelography - Mass Spectrometry - MRI Technician and Technologist Career - Calculation - Stimulator pool
 
Artirem®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Artirem®, the arthrography-specific contrast agent for MRI is a dilute form of Dotarem® with a less concentration of Gd (1:200). Artirem® has to be injected directly into the joints for better visualization and delimitation, of the ligament and tendon structures in particular.

Drug Information and Specification
NAME OF COMPOUND Gadoterate meglumine, Gd-DOTA
DEVELOPER Guerbet S.A.
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY r1=3.4, r2=4.8, B0=1.0T
PHARMACOKINETIC Intravascular, extracellular, renal excretion
CONCENTRATION 0,0025 mmol/ml
PREPARATION Finished product
INDICATION Arthrography
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Pre-filled syringes of 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU Dotarem® for sale Guerbet S.A.
France, Switzerland Artirem® for sale Guerbet S.A.
Australia Dotarem® for sale

spacer

• View the DATABASE results for 'Artirem®' (4).Open this link in a new window

MRI Resources 
DICOM - Service and Support - Breast MRI - Mobile MRI Rental - MRI Technician and Technologist Career - Safety Products
 
Contrast AgentsForum -
related threadsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Contrast agents are chemical substances introduced to the anatomical or functional region being imaged, to increase the differences between different tissues or between normal and abnormal tissue, by altering the relaxation times. MRI contrast agents are classified by the different changes in relaxation times after their injection.
Positive contrast agents cause a reduction in the T1 relaxation time (increased signal intensity on T1 weighted images). They (appearing bright on MRI) are typically small molecular weight compounds containing as their active element Gadolinium, Manganese, or Iron. All of these elements have unpaired electron spins in their outer shells and long relaxivities.
Some typical contrast agents as gadopentetate dimeglumine, gadoteridol, and gadoterate meglumine are utilized for the central nervous system and the complete body; mangafodipir trisodium is specially used for lesions of the liver and gadodiamide for the central nervous system.
Negative contrast agents (appearing predominantly dark on MRI) are small particulate aggregates often termed superparamagnetic iron oxide (SPIO). These agents produce predominantly spin spin relaxation effects (local field inhomogeneities), which results in shorter T1 and T2 relaxation times.
SPIO's and ultrasmall superparamagnetic iron oxides (USPIO) usually consist of a crystalline iron oxide core containing thousands of iron atoms and a shell of polymer, dextran, polyethyleneglycol, and produce very high T2 relaxivities. USPIOs smaller than 300 nm cause a substantial T1 relaxation. T2 weighted effects are predominant.
A special group of negative contrast agents (appearing dark on MRI) are perfluorocarbons (perfluorochemicals), because their presence excludes the hydrogen atoms responsible for the signal in MR imaging.
The design objectives for the next generation of MR contrast agents will likely focus on prolonging intravascular retention, improving tissue targeting, and accessing new contrast mechanisms. Macromolecular paramagnetic contrast agents are being tested worldwide. Preclinical data shows that these agents demonstrate great promise for improving the quality of MR angiography, and in quantificating capillary permeability and myocardial perfusion.
Ultrasmall superparamagnetic iron oxide (USPIO) particles have been evaluated in multicenter clinical trials for lymph node MR imaging and MR angiography, with the clinical impact under discussion. In addition, a wide variety of vector and carrier molecules, including antibodies, peptides, proteins, polysaccharides, liposomes, and cells have been developed to deliver magnetic labels to specific sites. Technical advances in MR imaging will further increase the efficacy and necessity of tissue-specific MRI contrast agents.
See also Adverse Reaction and Nephrogenic Systemic Fibrosis.

See also the related poll result: 'The development of contrast agents in MRI is'
 
Images, Movies, Sliders:
 Delayed Myocardial Contrast Enhancement from Infarct  Open this link in a new window
      

Courtesy of  Robert R. Edelman
 Left Circumflex Ischemia First-pass Contrast Enhancement  Open this link in a new window
 MR Colonography Gadolinium per Rectum  Open this link in a new window
      

Courtesy of  Robert R. Edelman
 CE MRA of the Aorta  Open this link in a new window
    
SlidersSliders Overview

 
Radiology-tip.comContrast Agents,  Safety of Contrast Agents
spacer
Radiology-tip.comUltrasound Contrast Agents,  Ultrasound Contrast Agent Safety
spacer

• View the DATABASE results for 'Contrast Agents' (122).Open this link in a new window


• View the NEWS results for 'Contrast Agents' (25).Open this link in a new window.
 
Further Reading:
  Basics:
A safer approach for diagnostic medical imaging
Monday, 29 September 2014   by www.eurekalert.org    
Contrast Agents in Magnetic Resonance Imaging
1997
MR contrast agents: Applications in hepatobiliary imaging
Thursday, 11 November 2010   by www.appliedradiology.com    
  News & More:
A natural boost for MRI scans
Monday, 21 October 2013   by www.eurekalert.org    
Drastic market changes with MRI contrast media and PET radiopharmaceuticals emerging as most promising segments
Thursday, 21 October 2004   by www.news-medical.net    
For MRI, time is of the essence A new generation of contrast agents could make for faster and more accurate imaging
Tuesday, 28 June 2011   by scienceline.org    
Searchterm 'Gadoterate Meglumine' was also found in the following service: 
spacer
News  (2)  
 
Dotarem®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Dotarem® is a paramagnetic ionic MRI contrast agent. Extracellular contrast agents like Dotarem®, can be bolus injected because of the relatively low rate of side effects. This contrast medium is useable to enhance signal intensity in magnetic resonance imaging for intracranial and spinal lesions with an abnormal blood brain barrier or abnormal vascularity, and in whole body imaging.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

Drug Information and Specification
NAME OF COMPOUND Gadoterate meglumine, Gd-DOTA
DEVELOPER Guerbet S.A.
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY r1=3.4, r2=4.8, B0=1.0T
PHARMACOKINETIC Intravascular, extracellular, renal excretion
OSMOLALITY 1350 mosm/kgH2O
CONCENTRATION 0.5 mol/L
DOSAGE 0.1 mmol/kg / 0.2mL/kg
PREPARATION Finished product
INDICATION Neuro/whole body
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Vials of 5, 10, 15, 20mL
Pre-filled syringes of 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU Dotarem® for sale Guerbet S.A.
France, Switzerland Artirem® for sale Guerbet S.A.
Australia Dotarem® for sale

spacer

• View the DATABASE results for 'Dotarem®' (7).Open this link in a new window

 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
  News & More:
Guerbet to Exhibit Recently U.S. Approved Imaging Agents at 100 Year Anniversary of RSNA
Thursday, 13 November 2014   by money.cnn.com    
MRI Resources 
Contrast Enhanced MRI - Colonography - Safety pool - Societies - Mobile MRI Rental - Jobs pool
 
     1 - 4 (of 4)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



The impact of TTIP/TPP on the MRI scanner market will bring :
more variety 
better scanners 
more risk 
less regulation 
cheaper scanners 
Lost in Translation 
no change at all 

Look
      Ups





Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2003 - 2016 SoftWays. All rights reserved. [ 24 February 2017]
Terms of Use | Privacy Policy | Advertising
 [last update: 2017-02-21 00:45:00]